The Motif of Human Cardiac Myosin-binding Protein C Is Required for Its Ca\(^{2+}\)-dependent Interaction with Calmodulin*

Received for publication, May 18, 2012, and in revised form, July 6, 2012. Published, JBC Papers in Press, July 16, 2012, DOI 10.1074/jbc.M112.383299

Yanling Lu, Ann H. Kwan, Cy M. Jeffries\(^1\), J. Mitchell Guss, and Jill Trewhella\(^2\)

From the School of Molecular Bioscience, Building G08, The University of Sydney, New South Wales 2006, Australia

Background: The motif of human cMyBP-C contains phosphorylation sites that regulate its interaction with myosin ΔS2.

Results: The motif interacts with calmodulin in a calcium-dependent manner yet is independent of its phosphorylation state.

Conclusion: Highly conserved residues toward the C-terminal end of the motif interact with calmodulin in an extended conformation.

Significance: Calmodulin can link cMyBP-C with the calcium-signaling pathways in muscle.

The N-terminal modules of cardiac myosin-binding protein C (cMyBP-C) play a regulatory role in mediating interactions between myosin and actin during heart muscle contraction. The so-called “motif,” located between the second and third immunoglobulin modules of the cardiac isoform, is believed to modulate contractility via an “on-off” phosphorylation-dependent tether to myosin ΔS2. Here we report a novel Ca\(^{2+}\)-dependent interaction between the motif and calmodulin (CaM) based on the results of a combined fluorescence, NMR, and light and x-ray scattering study. We show that constructs of cMyBP-C containing the motif bind to Ca\(^{2+}\)/CaM with a moderate affinity (\(K_D\) \(\approx\) 10 \(\mu\)M), which is similar to the affinity previously determined for myosin ΔS2. However, unlike the interaction with myosin ΔS2, the Ca\(^{2+}\)/CaM interaction is unaffected by substitution with a triphosphorylated motif mimic. Further, Ca\(^{2+}\)/CaM interacts with the highly conserved residues (Glu\(^{319}\)–Lys\(^{341}\)) toward the C-terminal end of the motif. Consistent with the Ca\(^{2+}\) dependence, the binding of CaM to the motif is mediated via the hydrophobic clefts within the N- and C-lobes that are known to become more exposed upon Ca\(^{2+}\) binding. Overall, Ca\(^{2+}\)/CaM engages with the motif in an extended clamp configuration as opposed to the collapsed binding mode often observed in other CaM-protein interactions. Our results suggest that CaM may act as a structural conduit that links cMyBP-C with Ca\(^{2+}\) signaling pathways to help coordinate phosphorylation events and synchronize the multiple interactions between cMyBP-C, myosin, and actin during the heart muscle contraction.

The controlled modulation of Ca\(^{2+}\) concentrations within muscle sarcomeres is the primary signaling mechanism used to regulate the sliding of myosin-based thick filaments past actin-based thin filaments to give rise to muscle contraction and relaxation. In striated muscle, Ca\(^{2+}\) activates the thin filament by binding to tropomyosin, thus triggering conformational changes among the thin filament accessory proteins. The result is a shift of tropomyosin on the thin filament that uncovers the binding sites where myosin heads attach to actin and impart force (1). However, there are additional layers of regulation that modulate the contractile cycle. We have previously proposed that the N-terminal modules of cardiac myosin-binding protein C can modulate the thin filament activation response to Ca\(^{2+}\) signals, essentially buffering the Ca\(^{2+}\) response by competing for myosin binding sites on actin while also sterically hindering tropomyosin from relaxing to its Ca\(^{2+}\)-off position and thus holding myosin binding sites on actin open (2, 3). Ca\(^{2+}\) signals also regulate the activity of a number of kinases important in muscle action, in a number of instances via the multifunctional intracellular Ca\(^{2+}\) receptor calmodulin (4–6). One such calmodulin-regulated kinase is Ca\(^{2+}\)/calmodulin-dependent protein kinase II (CaMKII)\(^3\) that phosphorylates a critical regulatory region within cMyBP-C (7, 8).

Calmodulin (CaM) is a small, dumbbell-shaped protein that is a structural homologue of the Ca\(^{2+}\)-binding subunit of tropomyosin (TnC), but rather than having a single known regulatory function, CaM binds to a diverse array of target proteins to modulate their functions in response to Ca\(^{2+}\) signals (4–6). The two globular lobes of CaM each contain a pair of Ca\(^{2+}\)-binding EF-hand (helix-loop-helix) motifs that are connected by a solvent-exposed helix of \(-8\) turns. Upon Ca\(^{2+}\) binding, a hydrophobic cleft opens in each lobe to mediate target protein recognition and binding. In the classical Ca\(^{2+}\)/CaM-target protein complexes, the two lobes of CaM wrap around a helical peptide sequence via flexibility in the interconnecting helix (6, 9). Other modes of Ca\(^{2+}\)/CaM binding have been observed in...
which CaM maintains an extended conformation (10–14) similar to those observed for TnC interacting with its regulatory binding partner troponin I (TnI) (15).

Myosin-binding protein C (MyBP-C) was first identified as a thick filament accessory protein and has since been determined to play both structural and regulatory roles in striated muscle contraction (16–18). MyBP-C is a modular protein made up of immunoglobulin (Ig)-type and fibronectin-like modules. An ~100-residue sequence, referred to as the “motif” (m), sits between two Ig modules near the N terminus (Fig. 1, A and B) and has been implicated in mediating potentially key phosphorylation-dependent interactions in the cardiac isoform (19). Interest in cardiac MyBP-C (cMyBP-C) has been stimulated following the finding that mutations in the gene encoding the cardiac isoform are a leading cause of familial hypertrophic cardiomyopathy (20–22). cMyBP-C contains eight Ig modules and three fibronectin modules, designated C0–C10. The C0 Ig module is cardiac specific and connects to C1 via a proline/alanine-rich linker (Fig. 1A). In addition, there are multiple cardiac specific phosphorylation sites compared with only one in the skeletal isoform (19). The C1-m-C2 fragment (C1C2) binds to myosin ΔS2, close to the lever arm region of the myosin head and primarily via the motif (23, 24). During β-adrenergic stimulation, cMyBP-C undergoes phosphorylation and releases the bound myosin ΔS2, resulting in an acceleration of the cross-bridge cycling rates and force generation (23, 25).

Both CaM kinase II and protein kinase A (PKA) can phosphorylate cMyBP-C on at least three serines within the motif (Ser275, Ser284, and Ser304 in the human sequence, corresponding to Ser273, Ser282, and Ser302 in mouse) (7, 8, 19, 26) (Fig. 1C). An ordered hierarchy of phosphorylation exists among these sites (23, 27, 28). In the mouse protein, Ser282 is the main target for CaM kinase II, and, importantly, phosphorylation at this site is necessary to induce further phosphorylation at Ser273 and Ser302 by PKA. The critical role of Ser282 phosphorylation by CaM kinase II is highlighted by its links to enhanced contractility after myocardial stunning (29, 30), whereas the loss of cMyBP-C phosphorylation at Ser282 results in altered response to β-adrenergic stimuli (31). The CaM kinase II-regulated phosphorylation is strictly Ca2+/CaM-dependent and can be inhibited by the Ca2+/chelator EGTA or the CaM-binding peptide sequence from myosin light chain kinase (MLCK) (7, 8, 19, 32). CaM kinase II inhibition reduces both cMyBP-C and TnI phosphorylation and decreases maximum force through a cross-bridge feedback mechanism (33). Together, the combined evidence suggests that Ca2+/CaM-dependent phosphorylation of cMyBP-C may be a key step for coordinating events in the contractile cycle. When directly isolated from muscle tissue, cMyBP-C is purified with endogenous CaM kinase activity (7), suggesting that there is an intimate link between the protein and this Ca2+/CaM-dependent kinase.

In addition to regulating CaM kinase activity, Ca2+ signals regulate the activity of the Ca2+/CaM-dependent MLCK that phosphorylates yet another EF-hand relative of CaM, the myosin regulatory light chain (RLC) (34–36). The CaM-dependent phosphorylation of cMyBP-C and RLC contribute to the contraction/relaxation cycle by modifying the local concentration of cross-bridges at the interface with actin (37). The CO domain of cMyBP-C can directly interact with the RLC (38), whereas the cMyBP-C motif, in an unphosphorylated state, can interact with myosin ΔS2 (24). Therefore, the N-terminal domains of cMyBP-C can interact with both components of myosin proximal to the myosin head and with actin (2, 39). It thus appears that Ca2+ signaling and CaM-dependent mechanisms of phosphorylation in response to these signals are integral to regulating molecular interactions between all three proteins. Because CaM is a pivotal Ca2+ sensor, we asked whether CaM may serve as a structural, Ca2+-sensitive link to the regulatory role of cMyBP-C.

In this study, we have used pull-down assays, size exclusion chromatography with multiple-angle laser light scattering spectroscopy (SEC-MALLS), tryptophan fluorescence, nuclear magnetic resonance (NMR) spectroscopy, and small angle x-ray scattering (SAXS) to identify and characterize a novel interaction between cMyBP-C and CaM. We have identified a region within the motif responsible for CaM binding and determined that the interaction is of moderate affinity, with CaM maintaining an extended conformation in the complex. We show that the interaction is Ca2+-dependent yet independent of the phos-

![Human cMyBP-C Motif Interacts with Calmodulin](image-url)

**FIGURE 1.** N-terminal modules and the motif of cMyBP-C. A, schematic representation of the three N-terminal Ig modules (C0, C1, and C2) and their connectors: the proline/alanine-rich linker (P/AL) and the motif (m). The approximate molecular weight (Mw) of each region is indicated, and the color coding for different regions of sequence/structure is conserved in panels A, B, and C. B, ribbon diagrams of (from left to right) the human C1 (PDB 2AVG) module, the structured region of mouse motif (residues 315–351) (PDB 2LHU), and the human C2 (PDB 1PD6) module with tryptophan residues in red. Note that Trp318 in the mouse sequence is equivalent to Trp322 in the human sequence. In the mouse motif ribbon diagram (middle), the sequence corresponding to human Cpep used in this study (incorporating Trp318) is shown in yellow, and the remaining sequence is orange. C, sequence alignments of human and mouse cMyBP-C motifs and of human motif peptides (Npep and Cpep). For the human motif, the three putative phosphorylation sites are marked by asterisks above the sequence, and the only tryptophan residue, Trp322, is highlighted in red. Sequences corresponding to the structured region of mouse motif (amino acids 315–351) are highlighted in yellow and orange as in B. Note that for the human triphosphorylation mimic C1C2EEE, the three putative phosphorylation sites are mutated to glutamates (i.e. S275E/S284E/S304E).
phorylation state of the motif. Our results provide the first structural evidence that cMyBP-C can access Ca\(^{2+}\) signaling pathways via a physical attachment to Ca\(^{2+}\)/CaM that could have consequences for synchronizing events between cMyBP-C and its binding partners in muscle filaments.

**EXPERIMENTAL PROCEDURES**

**Protein Expression and Purification**—The expression plasmids encoding the human cMyBP-C N-terminal constructs (C0-C1 \(\equiv\) C0C1, C1-m-C2 \(\equiv\) C1C2, C0-C1-m-C2 \(\equiv\) C0C2, and motif \(\equiv\) m) were prepared as described (40). The C1C2EEE triple glutamate mutant (S275E/S284E/S304E), which incorporates a stable trisphosphomimetic of the motif, was isolated from a synthetic C0C2EEE gene manufactured by Genscript Inc. employing the same protocol as described for the isolation of C0, C1, and C0C1 (3). All human cMyBP-C proteins were expressed in *Escherichia coli* Rosetta 2 cells and purified as described previously (41), whereas \(^{15}\)N-labeled C1C2 and the trisphosphomimetic C1C2EEE were produced using the procedures described previously (39). The final expressed recombinant protein included an in-frame N-terminal polyhistidine tag that was not removed due to the proteolytic sensitivity of the C1C2EEE protein. CaM and \(^{15}\)N-labeled CaM were expressed in *E. coli* Rosetta 2 cells and purified as described previously (42). Stock solutions of C1C2 and C1C2EEE were stored in a buffer containing 25 mM Tris, 350 mM NaCl, 2 mM TCEP, pH 7.0; stock solutions of the motif were stored in buffer containing 20 mM Tris, 50 mM NaCl, 2 mM TCEP, pH 6.8; and stock solutions of CaM were stored in a buffer containing 50 mM MOPS, 150 mM NaCl, and 10 mM CaCl\(_2\), pH 7.4. The two synthetic peptides were purchased from Genscript Inc. Their sequences are RDSFRTPRDSKLEAPAEEDVWEILR and EDVWEILRQAPPSHERIAFQYG, and they are referred to as Npep and Cpep, respectively. Prior to dialysis in titration or SAXS buffers, the lyophilized Npep or Cpep was dissolved in water and 10% acetic acid, respectively, to a final concentration of ~4 mg/ml.

**CaM-agarose Pull-down Assays**—CaM-agarose pull-down assays were performed to screen which of the purified C0, C0C1, C1C2, and C0C2 cMyBP-C fragments could bind CaM. Approximately 500 \(\mu\)l of each N-terminal fragment at 1 mg/ml in 25 mM MOPS, 50 mM KCl, 5 mM CaCl\(_2\), 2 mM TCEP, pH 7.0, was added to 100-\(\mu\)l aliquots of covalently linked CaM-agarose beads (Sigma) equilibrated in the same buffer. The protein/agarose bead slurries were left to incubate for ~15 min at 4 °C, with gentle mixing every 2 min to distribute the bead matrix in solution, before being spun at 10,000 \(\times\) g for 30 s to pellet the beads. The pelleted beads were sequentially resuspended/washed and spun four times using 500 \(\mu\)l of the aforementioned buffer to remove any unbound protein. This process was also repeated as described using a calcium-free buffer solution, where 5 mM CaCl\(_2\) was substituted by 10 mM EGTA throughout the protein binding and bead washing steps. To monitor cMyBP-C fragments binding to the CaM-agarose in the presence or absence of Ca\(^{2+}\), 20-\(\mu\)l aliquots of washed and spun beads were added to 10 \(\mu\)l of 25 mM Tris, pH 8.0, and 10 \(\mu\)l of 4× SDS-PAGE loading dye to form a 50% (v/v) bead/loading dye slurry. The slurry was subsequently boiled for 5 min and spun to repellet the beads, and 15 \(\mu\)l of supernatant from each individual sample was used for SDS-PAGE analysis.

**Size Exclusion Chromatography with Multiple-angle Laser Light Scattering**—SEC-MALLS experiments and data analyses were carried out following the procedures described previously (42). SEC-MALLS data were collected for purified Ca\(^{2+}\)/CaM, C1C2, and a mixture of Ca\(^{2+}\)/CaM plus \(^{15}\)N[C1C2 solution that contained excess Ca\(^{2+}\)/CaM (Ca\(^{2+}\)/CaM to \(^{15}\)N[C1C2 molar ratio of 2:1). Typically, ~400 \(\mu\)l of protein solution at ~100 \(\mu\)m was analyzed in a Superdex 75 10/30 gel filtration column (GE Healthcare) coupled with the miniDAWN light scattering unit (Wyatt Technology) and a DSP refractometer (Optilab). The system was equilibrated with a standard buffer containing 25 mM MOPS, 350 mM NaCl, 5 mM CaCl\(_2\), 2 mM TCEP, pH 7.0. Unless otherwise stated, this standard buffer was used in all of the SEC-MALLS, tryptophan fluorescence, and NMR titration experiments reported in this study. Following similar conditions and procedures, SEC-MALLS data were also acquired for purified Ca\(^{2+}\)/CaM, motif, and the Ca\(^{2+}\)/CaM-motif complex with excess Ca\(^{2+}\)/CaM (prepared by mixing Ca\(^{2+}\)/CaM and motif at a 2:1 molar ratio).

**Tryptophan Fluorescence Spectroscopy**—Fluorescence spectra of cMyBP-C protein or peptide samples (including C1C2, C1C2EEE, motif, Cpep, and Npep) and their corresponding buffer solutions were obtained at 25 °C using a Varian Eclipse fluorescence spectrophotometer following the same settings as described previously (42). Prior to the titration experiments, aliquots of the cMyBP-C protein or peptide and CaM stock solutions were individually dialyzed overnight against the standard buffer. To evaluate the Ca\(^{2+}\) dependence of the binding, the 5 mM CaCl\(_2\) in the standard buffer was replaced by 10 mM EGTA. The effect of ionic strength on the Ca\(^{2+}\)/CaM-C1C2 interaction was evaluated by reducing the concentration of NaCl in the standard buffer to 100 mM. Similarly, the binding of motif to Ca\(^{2+}\)/CaM was evaluated in a buffer containing 20 mM Tris, 50 mM NaCl, 5 mM CaCl\(_2\), 2 mM TCEP, pH 6.8.

At each titration step, aliquots of a concentrated CaM solution (>1 mM) were sequentially added to the cMyBP-C protein or peptide solution (~5 \(\mu\)M) and left to equilibrate for 10 min prior to recording their emission spectrum eight times. The eight spectra were averaged to produce the final spectrum. All averaged sample spectra were corrected for solvent effects by subtracting the emission spectra of the respective buffer across the full emission range. Dilution effects and the intrinsic fluorescence contribution from tyrosine were considered in the data analysis. Inner filter effects were checked for by sequentially titrating CaM stock into a standard tryptophan solution (~40 \(\mu\)M). No significant inner filter effects were observed for the amount of CaM used in all titration experiments (data not shown).

To determine the binding affinity (\(K_D\)) in each tryptophan fluorescence titration experiment, the relative fluorescence intensity \(F/F_0\) values (where \(F\) is the fluorescence intensity at each titration step, and \(F_0\) is the fluorescence intensity of Ca\(^{2+}\)-free (apo-) protein or peptide) at a chosen wavelength were plotted against the concentration of CaM and fitted to a quadratic equation based on a 1:1 binding model (e.g. see Ref. 43). For the Cpep/CaM titration data, the fit to the binding curve...
improved significantly when a concentration adjustment factor was included in the parameters. This adjustment factor typically ranged from 0.4 to 0.8, suggesting that the peptide concentration was lower than initially estimated from the extinction coefficient at 280 nm, possibly due to the low solubility of the peptide. For each set of titration data, the wavelength that gave the largest intensity changes between the apo and bound states was chosen for analysis. To achieve this, fluorescence spectra of the apo state and the last titration point were normalized to unity using their respective maximum intensity values. Subtraction of these normalized spectra yields the wavelength at which the largest intensity changes can be observed. Note that binding affinities can also be determined by plotting the changes in maximum emission wavelength $\lambda_{\text{max}}$ (i.e. the wavelength that maximal fluorescence intensity is observed) against concentrations of CaM. The $K_D$ values determined were essentially the same using $F/F_0$ or $\lambda_{\text{max}}$.

**NMR Spectroscopy**—$^1\text{H}-^{15}\text{N}$ HSQC spectra were recorded at 25 °C using a Bruker AVIII 800-MHz NMR spectrometer equipped with a triple-resonance cryogenic probe. Stock protein solutions were dialyzed against the standard buffer overnight, and the final protein concentrations used in titration experiments were ~100 $\mu$M for $^{15}\text{N}$C1C2 and $^{15}\text{N}$C1C2EE and ~130 $\mu$M for $^{15}$N-labeled Ca$^{2+}$/CaM. D$_2$O was added to each sample to a final concentration of 10% (v/v). Sodium 2,2-dimethyl-2-silapentane-5-sulfonate was used as the internal chemical shift reference. Spectra were processed with Topspin (T. D. Goddard and D. G. Kneller, University of California, San Francisco). Chemical shift assignments for $^{15}\text{N}$C1C2, $^{15}\text{N}$C1C2EEE, and $^{15}\text{N}$CaM were inferred using previously published chemical shift assignments (BMRB accession number 6015 for C1, BMRB 5591 for C2, BMRB 17867 for motif, and BMRB 547 for CaM). The indole nitrogens of residues Trp$^{196}$, Trp$^{322}$, and Trp$^{396}$ were assigned based on Ref. 44. $^1\text{H}-^{15}\text{N}$ HSQC spectra of $^{15}\text{N}$C1C2 were recorded after sequential additions of unlabeled Ca$^{2+}$/CaM stock solution (1.2 mm) to obtain molar ratios of [Ca$^{2+}$/CaM]/[$^{15}\text{N}$C1C2] at 0.2:1, 0.4:1, 0.8:1, 1:1, and 2:1. For each addition, the solutions were mixed and equilibrated for 10 min before spectra were recorded. Relative peak heights (using the spectrum of $^{15}\text{N}$C1C2 alone as a reference) for all identifiable and non-overlapped residues at each titration step were plotted. Residues that underwent significant intensity changes were defined as those with peak heights decreasing by more than one S.D. value from the average. Similar NMR experiments and data analyses were carried out using $^{15}\text{N}$C1C2EE with molar ratios of [Ca$^{2+}$/CaM]/[$^{15}\text{N}$C1C2EEE] at 0.3:1, 0.6:1, 1:1, and 2:1.

For the reverse titrations of $^{15}$N-labeled Ca$^{2+}$/CaM with unlabeled C1C2, $^1\text{H}-^{15}\text{N}$ HSQC spectra of $^{15}$N-labeled Ca$^{2+}$/CaM were recorded with sequential additions of unlabeled C1C2 stock solution (~140 $\mu$M) to obtain molar ratios of [$^{15}$N]Ca$^{2+}$/CaM]/[C1C2] at 1.0:2, 1.0:3, 1.0:4, 1.0:5, 1.0:75, and 1:1. Data analyses were carried out as described except that the spectrum of $^{15}$N-labeled Ca$^{2+}$/CaM was used as the reference. The experiment was repeated for $^{15}$N-labeled Ca$^{2+}$/CaM (~70 $\mu$M) and Cpep. Final molar ratios of [$^{15}$N]Ca$^{2+}$/CaM]/[Cpep] used were 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.85, 1:1, 1:1.5, 1:2, 1:3, and 1:4. For the Cpep titration, spectral changes presented mainly as positional rather than intensity changes; therefore, combined chemical shift perturbations ($\Delta \delta_{\text{ppm}}$) were calculated based on the equation, $\Delta \delta_{\text{ppm}} = (\Delta \delta_{\text{HN}})^2 + (0.154 \times \Delta \delta_{\text{C}})^{1/2}$, where $\Delta \delta_{\text{HN}}$ and $\Delta \delta_{\text{C}}$ represent the chemical shift variations in the proton and nitrogen dimensions, respectively. Residues with positions changed by more than one S.D. value from the mean were deemed to be significantly affected. Binding affinity was determined from fitting to a 1:1 binding model using $\Delta \delta_{\text{ppm}}$ of residues Ala$^{57}$, Val$^{121}$, and Ile$^{130}$ at varying concentrations of Cpep.

**SAXS Data Acquisition, Analysis, and Modeling**—Ca$^{2+}$/CaM was freshly prepared from gel filtration in the standard buffer and immediately concentrated for SASSS measurements. For Ca$^{2+}$/CaM-Cpep, the complex was prepared by simply mixing the Ca$^{2+}$/CaM and Cpep solutions at a 1:3 molar ratio (note that the excess Cpep does not contribute significantly to the scattering intensity due to its small molecular volume). SAXS data were acquired at 10 °C using a SAXSess instrument (Anton Paar, Graz, Austria) with 10-μm line collimation and a charge-coupled device (CCD) detector. All data reduction and analyses followed the procedures described previously (40). Low resolution ab initio shape reconstructions were performed using the program DAMMIF (45) as described previously (41). The NSD values of each set of 10 DAMMIF models were 0.621 ± 0.012 for Ca$^{2+}$/CaM and 0.557 ± 0.015 for Ca$^{2+}$/CaM-Cpep, respectively.

**RESULTS**

$c\text{MyBP-C Fragments Containing Motif-C2 Bind to Ca}^{2+}$/Calmodulin—Pull-down assays were performed by incubating CaM-agarose beads with N-terminal fragments of human cMyBP-C (C0C1, C1, C1C2, and C0C2) in the presence and absence of Ca$^{2+}$ (Fig. 2). Only C1C2 and C0C2, each of which includes the motif and C2, show significant binding to CaM-agarose, and this binding is Ca$^{2+}$-dependent. C1C2 and C0C2 appear to be pulled down to similar extents, suggesting that C0 is not involved in the interaction and that the Ca$^{2+}$/CaM binding region exists within the motif and/or C2 domain.

Based on the qualitative pull-down assessments, a solution containing C1C2 and Ca$^{2+}$/CaM in molar excess was subjected to SEC-MALLS. The results indicate that the first and predominant peak eluting from the column corresponds to a species with an experimental molecular mass of 48.9 ± 0.2 kDa, consistent with the theoretical molecular mass of 52 kDa for a 1:1 Ca$^{2+}$/CaM-C1C2 complex, whereas a second elution peak corresponds to excess Ca$^{2+}$/CaM (data not shown).

Tryptophan fluorescence was then used to confirm and further characterize the binding between C1C2 and Ca$^{2+}$/CaM. CaM-binding proteins commonly have a tryptophan in their CaM recognition sequences (6, 9), which makes tryptophan fluorescence spectroscopy useful for probing CaM interactions, especially because CaM itself contains no tryptophans. There are four tryptophans in C1C2: Trp$^{191}$, Trp$^{196}$, Trp$^{322}$, and Trp$^{396}$. Based on the NMR and crystal structures of the C1 and C2 domains (44, 46, 47), there is one tryptophan located in the central hydrophobic core of each of the C1 and C2 domains.

Human cMyBP-C Motif Interacts with Calmodulin
Human cMyBP-C Motif Interacts with Calmodulin

![Graph showing fluorescence intensity vs. wavelength for C1C2 and C1C2EEE titrations with Ca2+/CaM](image)

**FIGURE 2.** SDS-PAGE pull-down assays indicating interactions between different cMyBP-C N-terminal fragments and CaM. The effects of Ca2+ on the interactions are tested by comparing results obtained in the presence of Ca2+ or with EGTA. Samples in lanes from left to right are as follows: Lane 1, molecular weight (Mw) standards; lane 2, CaM-agarose beads only; lanes 3 and 4, C0C1 + CaM-agarose; lanes 5 and 6, C1 + CaM-agarose; lanes 7 and 8, C1C2 + CaM-agarose; lanes 9 and 10, C0C2 + CaM-agarose. For each of the paired lanes (lanes 3 and 4, 5 and 6, 7 and 8, and 9 and 10), the left lane is with Ca2+, and the right is with EGTA. The calculated molecular masses for C0C2, C0C1, C1C2, and C1 are 49, 27, 33, and 11 kDa, respectively, based on their amino acid sequences. C0C1 and C1 both consistently migrate at “larger than expected” molecular masses.

As Ca2+/CaM was titrated into a C1C2 solution, a shift of the tryptophan emission peak was observed, with the maximum emission wavelength $\lambda_{max}$ changing from ~345 to ~336 nm; the blue shift is accompanied by a decrease in the maximum fluorescence intensity (Fig. 3). Tryptophan quenching is dominated by its carbonyl group and is very sensitive to changes in its fluorescence intensity (Fig. 3). Tryptophan quenching is dominated by its carbonyl group and is very sensitive to changes in its fluorescence intensity (Fig. 3). The calculated molecular masses for C0C2, C0C1, C1C2, and C1 are 49, 27, 33, and 11 kDa, respectively, based on their amino acid sequences. C0C1 and C1 both consistently migrate at “larger than expected” molecular masses.

(Trp$^{191}$ and Trp$^{196}$, respectively), Trp$^{196}$ is located on the outer surface of the C1 domain, and forms part of the β-barrel, and Trp$^{322}$ resides within the motif (Fig. 1B).

As Ca2+/CaM was titrated into a C1C2 solution, a shift of the tryptophan emission peak was observed, with the maximum emission wavelength $\lambda_{max}$ changing from ~345 to ~336 nm; the blue shift is accompanied by a decrease in the maximum fluorescence intensity (Fig. 3). Tryptophan quenching is dominated by its carbonyl group and is very sensitive to changes in its fluorescence intensity (Fig. 3). Tryptophan quenching is dominated by its carbonyl group and is very sensitive to changes in its fluorescence intensity (Fig. 3). The calculated molecular masses for C0C2, C0C1, C1C2, and C1 are 49, 27, 33, and 11 kDa, respectively, based on their amino acid sequences. C0C1 and C1 both consistently migrate at “larger than expected” molecular masses.

Over ~80% of the amide resonances of C1 and C2 in $^{15}$N]C1C2 could be inferred readily from the reported assignments. In contrast, the motif contributes to a substantial proportion of the unidentified peaks in the $^{15}$N]C1C2 spectrum with 1H chemical shifts between 8 and 9 ppm typical of disordered regions. Recently, Howarth et al. (50) reported NMR results showing that residues 315–351 of the 103-residue mouse motif form a small three-helical bundle (Fig. 1B), whereas the remainder of the motif is unstructured. The mouse cMyBP-C motif shares ~89% sequence identity with the human isoform (Fig. 1C), with only one amino acid difference in the three-helical bundle (Tyr$^{346}$ for human versus His$^{336}$ for mouse). However, despite the high degree of sequence similarity, only ~30% of amide assignments from the small three-helical bundle of the mouse motif (BMRB accession number 17867) could be confidently matched to corresponding peaks in our $^{15}$N]C1C2 spectrum due to spectral overlap, especially in the region of the spectrum dominated by disordered structures.

Upon the addition of Ca2+/CaM to $^{15}$N]C1C2, a subset of peaks in the $^{15}$N-H HSQC NMR spectrum displayed a severe drop in signal intensity, with some peaks disappearing completely (Fig. 4). Specifically, ~66% of the amide resonance peaks mapped to the structured region of the motif showed significant intensity changes upon binding to Ca2+/CaM, including those assigned to Ala$^{317}$, Ile$^{324}$, Arg$^{326}$, Ala$^{328}$, Tyr$^{333}$, Glu$^{334}$, Arg$^{346}$, Lys$^{350}$, and Arg$^{351}$ that disappeared completely. In contrast, only a handful of peaks mapped to C1 and C2 were affected. In addition, a large proportion of peaks in the disordered region, which are likely to correspond to the unstructured residues within the motif, disappeared during the titra-
Human cMyBP-C Motif Interacts with Calmodulin

TABLE 1

Binding affinities ($K_d$) of cMyBP-C protein or peptide binding to Ca$^{2+}$-CaM determined from tryptophan fluorescence experiments

Unless otherwise stated, a standard buffer containing 25 mM MOPS, 350 mM NaCl, 5 mM CaCl$_2$, 2 mM TCEP, pH 7.0, was used. $R^2$ values describe the goodness of fit of titration data, with $R^2$ of 1 indicating that the experimental values match exactly with the predicted values using a 1:1 model.

| Peptide     | C1C2 (in 100 mM NaCl) | C1C2 (in EGTA) | C1C2EEE | Motif | Motif (in 50 mM NaCl) | Cpep | Npep |
|-------------|-----------------------|----------------|----------|-------|-----------------------|------|------|
| $K_d$ ± S.D. (μM) | 13.5 ± 2.5 | 8.7 ± 3.0 | >120 | 6.6 ± 1.7 | 4.3 ± 1.2 | 2.4 ± 0.3 | 4.3 ± 1.3 | >400 |
| $R^2$      | 0.998 | 0.996 | 0.994 | 0.994 | 0.999 | 0.999 | 0.998 | 0.999 |

![Overlay of 15N HSQC spectra of human C1C2 before (cyan) and after the addition of Ca$^{2+}$/CaM (magenta) at a molar ratio of 1:1 ([15N]C1C2)/[Ca$^{2+}$/CaM]). Inset, chemical shift changes of indole resonances of Trp196, Trp322, and Trp396.

The majority of the CaM minimal binding sequences characterized to date are 16–30 residues in length (9, 51, 52), with two large hydrophobic residues positioned to interact with the two CaM lobes. Hence, we considered whether the minimum binding region in cMyBP-C could be substantially shorter than the 97-residue motif. Because our fluorescence and NMR results suggest that Trp$^{322}$ is likely to be critical for anchoring Ca$^{2+}$/CaM, two peptides containing Trp$^{322}$ and at least one candidate for a second hydrophobic anchor were tested for binding Ca$^{2+}$/CaM using tryptophan fluorescence. The sequences selected were an 18-residue peptide from the sequence mainly upstream of Trp$^{322}$ (Arg$^{309}$–Lys$^{326}$, termed Npep) and an alternate 23-residue peptide from the sequence mainly downstream of Trp$^{322}$ (Glu$^{319}$–Lys$^{344}$, termed Cpep) (Fig. 1C). Significantly, Cpep binds to Ca$^{2+}$/CaM with an affinity (i.e. $4.3 ± 1.3$ μM) comparable with that of the motif, whereas Npep displays negligible binding (Fig. 5 and Table 1). Therefore, Cpep appears to contain most or all of the amino acid sequence that is important for the Ca$^{2+}$/CaM interaction.

FIGURE 4. [15N]C1C2 NMR titration with Ca$^{2+}$/CaM. Overlay of 15N HSQC spectra of human C1C2 before (cyan) and after the addition of Ca$^{2+}$/CaM (magenta) at a molar ratio of 1:1 ([15N]C1C2)/[Ca$^{2+}$/CaM]). Inset, chemical shift changes of indole resonances of Trp$^{196}$, Trp$^{322}$, and Trp$^{396}$.
more tightly than the N-lobe. The relatively large variations in the fitted dissociation constants and the associated errors probably reflect that the exchange regime is not strictly fast (but rather fast-intermediate), leading to errors with peak position determination. Nonetheless, the overall binding affinity for the C-terminal lobe as determined by NMR is consistent with binding affinities determined from the tryptophan fluorescence experiments (Table 1).

To confirm that the binding mode of Ca\(^{2+}\)/CaM is conserved between its interaction with Cpep and in the context of cMyBP-C, the \(^{15}N\) HSQC titration experiment was also carried out using the larger construct C1C2. Upon the addition of C1C2 to \(^{15}N\)-labeled Ca\(^{2+}\)/CaM, many peaks in the \(^{15}N\) HSQC spectrum experienced a severe drop in signal intensity and disappeared (Fig. 7A). The 15 amide resonance peaks that were deemed to have experienced significant intensity changes (namely Ser17, Phe19, Thr29, Leu48, Ala57, Ile\(^63\), Glu67, Leu69, Thr70, Met71, Met72, Ala88, Leu105, Glu120, Glu123, Ile130, and Met144) when bound to C1C2 again mapped specifically to the hydrophobic clefts in each of the two lobes of CaM, similar to the result for Cpep (Fig. 7B). Therefore, the binding mode is likely to be conserved between Cpep and C1C2.

Ca\(^{2+}\)/CaM Has an Extended Conformation in Its Complex with Cpep—SAXS was used to determine the solution conformation of the Ca\(^{2+}\)/CaM-Cpep complex. The scattering profiles of Ca\(^{2+}\)/CaM and its complex with Cpep are shown in Fig. 8A, and the associated structural parameters are summarized in Table 3. Guinier plots for Ca\(^{2+}\)/CaM and Ca\(^{2+}\)/CaM-Cpep (Fig. 8B, inset) are linear, consistent with the proteins in solution being predominantly monodisperse. AutoPord (54) calculations yield volumes consistent with the expected molecular mass based on amino acid content. The probable distribution of distances between atom pairs \(P(r)\) profiles calculated using GNOM (55); Fig. 8B) yields forward scattering intensity \(I(0)\) and radius of gyration \(R_g\) values in good agreement with those determined from the Guinier plots as well as the maximum linear dimension \(D_{\text{max}}\) for the scattering particles. The structural parameters of Ca\(^{2+}\)/CaM \((R_g = 22.3 \text{ Å}, D_{\text{max}} = 70 \text{ Å})\) agree reasonably with previously reported values (42, 56, 57) except that the \(R_g\) value is \(~1 \text{ Å} (i.e. 5\%)\) larger, probably due to the high salt concentrations in these samples. The Ca\(^{2+}\)/CaM-Cpep complex has \(R_g\) and \(D_{\text{max}}\) values of 23.3 and 75 Å, respectively, each slightly larger than those for the unbound Ca\(^{2+}\)/CaM. Thus, unlike the classical short helical peptides that bind CaM, there is no conformational collapse of CaM upon binding Cpep. Consistent with this, the \(P(r)\) profile of Ca\(^{2+}\)/CaM-Cpep is similar in shape to that for CaM alone, although with a less pronounced shoulder at \(~r = 45 \text{ Å}\) (Fig. 8B) that is probably accounted for by the fact that the peptide occupies space that results in less of a “dumbbell” shape compared with CaM alone. 

Ab initio shape reconstructions (Fig. 8C) also show that Ca\(^{2+}\)/CaM-Cpep is similarly extended as the unbound Ca\(^{2+}\)/CaM with the extra mass evident that can be attributed to the bound Cpep. The scattering data are thus consistent with the NMR results indicating that Cpep interacts with both lobes of Ca\(^{2+}\)/CaM.

It is well documented for Ca\(^{2+}\)/CaM that whereas the two hydrophobic lobes are folded into globular domains, the central...
helix contains a flexible region (residues 77–81) that facilitates the two lobes binding peptide sequences of different lengths and composition (6, 9). Kratky plots of Ca\(^{2+}\)/H11001/CaM and Ca\(^{2+}\)/H11001/CaM-Cpep complex are consistent with largely folded globular proteins with some flexibility (data not shown). It appears that this flexibility is retained to a similar degree in the Ca\(^{2+}\)/H11001/CaM-Cpep complex as in Ca\(^{2+}\)/H11001/CaM alone, consistent with the NMR titration experiments with \({\text{15N}}\)-labeled Ca\(^{2+}\)/H11001/CaM-Cpep showing that residues within the central helix do not experience large chemical shift changes when the two lobes bind to Cpep.

The Interaction between Ca\(^{2+}\)/CaM and Motif Is Phosphorylation-independent—Typically C1C2 is unphosphorylated following expression in bacteria (58). To determine the specific role of the phosphorylation-induced change in charge, we generated a mutant that is a triphosphomimic, C1C2EEE, by substituting glutamate (E) for serine (S) at the CaMKII (S284E) and PKA phosphorylation sites (S275E and S304E) of human C1C2 (Fig. 1C). Interestingly, C1C2EEE binds to Ca\(^{2+}\)/CaM in a very similar fashion and with an affinity comparable with that of the wild-type C1C2 as monitored by tryptophan fluorescence (Fig. 3 and Table 1). The \(1H-15N\) HSQC spectra of \(15N\)-labeled C1C2EEE and \(15N\)-labeled C1C2 overlay very well (data not shown) with few differences, which are located mainly in the region associated with disordered structure and probably corresponded to residues in close proximity to the three Ser to Glu mutations. It appears that these mutations do not induce large conformational changes in the C1 and C2 domains or in the

![FIGURE 6. Cpep-binding interfaces of Ca\(^{2+}\)/CaM. A, weighted chemical shift changes \(\Delta\delta_{\text{HN, H}}\) (ppm) for assigned residues of \(15N\)-labeled Ca\(^{2+}\)/CaM following the addition of Cpep at a molar ratio of 4:1 (Cpep/\(15N\)CaM). The horizontal line indicates 1 S.D. above the mean chemical shift change. Red bars correspond to residues deemed to have undergone significant chemical shift changes (>1 S.D.). Cyan bars correspond to residues that underwent even larger chemical shift changes but could not be traced during the titration or did not reappear in the spectrum. B, annotated structure of Ca\(^{2+}\)/CaM (PDB 1CCL) showing the locations of the perturbed residues as identified in A. Residues corresponding to cyan bars and red bars in A are shown as cyan and red spheres, respectively. Bound calcium atoms are shown as black spheres. For clarity, the left panel highlights only the cyan spheres, and the right panel highlights both cyan and red spheres. C, examples of the fitted binding curves for residues in fast exchange, including Ala\(^5\), Val\(^{121}\), and Ile\(^{130}\) (see Table 2 for corresponding \(K_d\) values).

**TABLE 2**

Binding affinities (\(K_d\)) of residues that underwent signal fast exchange during the titration of \(15N\)-labeled Ca\(^{2+}\)/CaM with Cpep

\(R^2\) values describe the goodness of fit of titration data with \(R^2\) of 1, indicating that the experimental values matched with the predicted values using a 1:1 model.

| Residue | \(K_d\) ± S.D. (M) | \(R^2\) |
|---------|--------------------|--------|
| Phe\(^{16}\) | 47.3 ± 8.1 | 0.997 |
| Val\(^{55}\) | 59.2 ± 16.2 | 0.994 |
| Ala\(^{57}\) | 4.9 ± 2.3 | 0.990 |
| Thr\(^{58}\) | 28.4 ± 9.6 | 0.990 |
| Arg\(^{54}\) | 24.4 ± 5.6 | 0.995 |
| Lys\(^{115}\) | 9.3 ± 5.2 | 0.983 |
| Leu\(^{116}\) | 5.3 ± 2.3 | 0.986 |
| Val\(^{121}\) | 9.4 ± 4.4 | 0.990 |
| Ile\(^{130}\) | 4.6 ± 2.2 | 0.990 |
motif. In particular, the indole resonances of \([15N]C1C2EEE\) overlay well with those of \([15N]C1C2\), suggesting that the chemical environment around the four tryptophan residues (including Trp322 in the motif) remain the same in C1C2EEE as in C1C2. Consistent with results from tryptophan fluorescence experiments, \(^1\)H-\(^{15}\)N HSQC spectra of \([15N]C1C2EEE\) titrated with unlabeled Ca\(^{2+}\)/CaM show patterns of resonance intensity changes similar to those of \([15N]C1C2\), confirming that \([15N]C1C2EEE\) interacts with Ca\(^{2+}\)/CaM similarly to \([15N]C1C2\) (data not shown) with Trp322 in the motif of \([15N]C1C2EEE\) also directly interacting with Ca\(^{2+}\)/CaM.

**DISCUSSION**

By combining pull-down assays, SEC-MALLS, tryptophan fluorescence, and NMR titration data, we have identified a novel interaction between the N-terminal fragment C1C2 of human cMyBP-C and CaM. Previous co-sedimentation assays have failed to detect this interaction (59). The 1:1 stoichiometric interaction is Ca\(^{2+}\)/CaM-dependent and independent of ionic strength. Furthermore, we conclude that the motif that links the C1 and C2 modules is required for the complex formation and that a 23-residue sequence (i.e., residues Glu319–Lys341) at the C-terminal end of the motif is sufficient for maintaining this interaction.
Human cMyBP-C Motif Interacts with Calmodulin

TABLE 3
Structural parameters for CaM and Ca\(^{2+}\)/CaM-Cpep complex

| Parameter | Ca\(^{2+}\)/CaM | Ca\(^{2+}\)/CaM-Cpep |
|-----------|----------------|---------------------|
| 1\((0)\) (cm\(^{-1}\)) (from P(r)) | 0.0524 ± 0.0006 | 0.0477 ± 0.0004 |
| R\(_c\) (Å) (from P(r)) | 22.3 ± 0.3 | 23.2 ± 0.2 |
| 1\((0)\) (cm\(^{-1}\)) (from Guinier) | 0.0522 ± 0.0004 | 0.0474 ± 0.0005 |
| R\(_c\) (Å) (from Guinier) | 21.7 ± 0.5 | 23.0 ± 0.3 |
| \(D_{iso}\) (Å) | 70 | 75 |

\(M\) estimates

| Partial specific volume (cm\(^3\)g\(^{-1}\)) | 0.723 | 0.728 |
| Contrast (\(\Delta P \times 10^{10} \text{ cm}^{-2}\)) | 2.978 | 2.962 |
| Concentration from \(A_{20,000}\) (mgml\(^{-1}\)) | 4.3 | 2.3 |
| \(M\), from \(1\)\((0)\) | 15,509 (7%) | 26,247 (34%)* |
| \(M\), from AutoPorod | 15,620 (6%) | 19,567 (0%)* |
| \(M\), DAMMIF volume/2 | 17,000 (2%) | 21,700 (11%)* |
| Calculated monomeric \(M\), from sequence | 16,700 | 19,500 |

* The relatively large error in \(M\), determined from \(1\)\((0)\) is due to the low solubility of Cpep.

interaction. This 23-residue peptide (Cpep) has no obvious consensus with any reported CaM-target sequences identified to date (5, 6, 51). Nevertheless, the formation of a Ca\(^{2+}\)/CaM-C1C2 complex appears to be specific because NMR titration data confirm that a number of hydrophobic residues from both motif and Ca\(^{2+}\)/CaM are involved in the complex formation. The interaction of Ca\(^{2+}\)/CaM with the motif via the hydrophobic clefts within the two Ca\(^{2+}\)-binding lobes of CaM, as has been observed in all CaM-target complexes (5, 6, 9), and as is commonly observed the C-lobe of CaM appears to interact slightly more strongly with the motif than the N-lobe does. In addition, our results show that basic residues and methionine residues of \(^{15}\)N-labeled Ca\(^{2+}\)/CaM are among the residues that undergo large chemical shift changes during titrations with Cpep, indicating that these residues are important for the complex formation, again consistent with previous suggestions that they act to optimize the contacts between CaM and the hydrophobic interface of its target protein (6, 9). It is likely that the tryptophan residue (Trp\(^{322}\)) within the motif is involved in anchoring to Ca\(^{2+}\)/CaM, similar to what has been observed in other known CaM-target peptides (6, 9–14). It is noteworthy that residue Trp\(^{322}\), together with most of the residues included in the 23-residue Cpep sequence, is highly conserved between isoforms and species of myosin-binding protein C (19, 24), arguing that its ability to bind to Ca\(^{2+}\)/CaM could be a crucial function of the protein. Consistent with this idea, seven mutations linked to hypertrophic cardiomyopathy have been identified in the gene encoding this 23-residue sequence (including single amino acid substitutions, such as R326Q, E334K, V342D, and L352P, and frameshift mutations at positions, such as Gln\(^{327}\), Thr\(^{343}\), and Met\(^{348}\)) (60).

In the context of CaM-binding sequences commonly being helical, it is interesting that the equivalent Cpep sequence forms two short \(\alpha\)-helices within a three-helical bundle in the mouse motif structure (50) (Fig. 1B). In this configuration, residue Trp\(^{322}\) lies within the hydrophobic core of the three-helical bundle, whereas for the shorter Cpep that does not include the third helix, Trp\(^{322}\) is likely to be more solvent-exposed. Consistent with this idea, the tryptophan fluorescence intensity increases for Cpep as it binds to Ca\(^{2+}\)/CaM, whereas intensity decreases are observed for all constructs containing an intact motif upon binding (Figs. 3 and 5). Unlike the classic collapsed conformations of CaM observed when binding short helical target sequences (6, 9), the SAXS data show that Cpep binds to an extended Ca\(^{2+}\)/CaM. Of note, the maximum length of the two helices of Cpep (∼38 Å) is sufficient to span the two Ca\(^{2+}\)-binding lobes of CaM in its extended formation. Taken together, our data suggest that CaM probably induces conformational changes within the structured three-helical bundle of the motif to expose and position Trp\(^{322}\) for binding; one way this could be achieved is through hinge motions at the junctions connecting the helices.

At Ca\(^{2+}\) concentrations below the threshold for muscle contraction, Ca\(^{2+}\)-regulated changes in phosphorylation of cMyBP-C are related to changes in cardiac contractility (28). Activation of CaMKII requires Ca\(^{2+}\)/CaM for autophosphorylation prior to its phosphorylating Ser\(^{292}\) in the motif (19, 61). Thus, the Ca\(^{2+}\)-dependent interaction between the motif and CaM may be functionally important to the timing and sequence of phosphorylation events that regulate cMyBP-C attachment and detachment from myosin ΔS2. Interestingly, the interaction reported here is independent of the phosphorylation state of the motif because both C1C2 and the triphosphomimic C1C2EEE bind to Ca\(^{2+}\)/CaM with micromolar affinity. C1C2 (predominantly via the motif) has also been found to bind to myosin ΔS2 with a \(K_D\) of ∼5 \(\mu M\) (24), which is comparable with its binding affinity with Ca\(^{2+}\)/CaM as identified in this study. However, the interaction between C1C2 and myosin ΔS2 can be abolished by phosphorylation of the motif (23). Therefore, the motif appears to interact with Ca\(^{2+}\)/CaM in a region structurally independent from the three phosphorylation sites so that phosphorylation of mutation of these sites has no impact on its interaction with Ca\(^{2+}\)/CaM. Consistent with this idea, we have identified residues involved in direct interactions with Ca\(^{2+}\)/CaM clustered at the structured C-terminal end of the motif.

In light of the fact that Ca\(^{2+}\)/CaM binds to the motif independently of its apparent phosphorylation state, it is interesting to consider the idea that this interaction could provide a means to store and readily supply Ca\(^{2+}\)/CaM. For example, CaMKII requires Ca\(^{2+}\)/CaM to initiate the first phosphorylation event necessary for additional phosphorylation events in the motif. Alternatively, when C1C2 is bound to myosin ΔS2, the bound Ca\(^{2+}\)/CaM on the motif may also facilitate phosphorylation of neighboring myosin RLC via the Ca\(^{2+}\)/CaM-dependent MLCK to promote myosin cross-bridge formation (34, 62). The micro-
molar range binding affinity between motif and Ca$^{2+}$/CaM is weaker than affinities reported for most CaM-target proteins ($K_D$ values between 0.1 μM and 0.01 nM) (6, 52); therefore, these CaM-regulated proteins, in particular CaMKII and MLCK, which are responsible for modulating contractile events, could compete with the motif for Ca$^{2+}$/CaM. Upon autophosphorylation of CaMKII or MLCK, CaM would be released and bind to the motif of cMyBP-C for storage.

The role of the interaction between Ca$^{2+}$/CaM and the motif of cMyBP-C reported in this study has yet to be fully understood in the context of the complex molecular networks that regulate muscle contraction. Nonetheless, our observations provide the first evidence that CaM can link cMyBP-C with the Ca$^{2+}$ signaling pathways in muscle, which opens the possibility of the interaction playing a role in synchronizing key regulatory phosphorylation events.

Acknowledgment—We thank Dr. Paul Rosevear for providing the mouse motif assignments.

REFERENCES

1. Geeves, M. A., and Holmes, K. C. (2005) The molecular mechanism of muscle contraction. Adv. Protein. Chem. 71, 161–193
2. Whitten, A. E., Jeffries, C. M., Harris, S. P., and Trewella, J. (2008) Cardiac myosin-binding protein C decorates F-actin. Implications for cardiac function. Proc. Natl. Acad. Sci. U.S.A. 105, 18360–18365
3. Orlova, A., Galkin, V. E., Jeffries, C. M., Egelman, E. H., and Trewhella, J. (2011) The N-terminal domains of myosin-binding protein C can bind polymorphically to F-actin. J. Mol. Biol. 412, 379–386
4. Chin, D., and Means, A. R. (2000) Cardiomylin. A prototypical calcium sensor. Trends Cell Biol. 10, 322–328
5. Vetter, S. W., and Lederc, E. (2003) Novel aspects of calmodulin target recognition and activation. Eur. J. Biochem. 270, 404–414
6. Crivici, A., and Ikura, M. (1995) Molecular and structural basis of target recognition by calmodulin. Annu. Rev. Biophys. Biomol. Struct. 24, 85–116
7. Hartzell, H. C., and Glass, D. B. (1984) Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca$^{2+}$-calmodulin-dependent protein kinases. J. Biol. Chem. 259, 15587–15596
8. Schröder, K. K., and Bean, L. J. (1991) Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. J. Biol. Chem. 266, 2811–2817
9. Yamniuk, A. P., and Vogel, H. J. (2004) Cardiomylin’s flexibility allows for promiscuity in its interactions with target proteins and peptides. Mol. Biotechnol. 27, 33–57
10. Rodríguez-Cañedano, F., Maestre-Martínez, M., Coudeville, N., Dimova, K., Junge, H., Lipstein, N., Lee, D., Becker, S., Brose, N., Jahn, O., Carlomagno, T., and Grõesinger, C. (2010) Modular architecture of Munc13/calmodulin complexes. Dual regulation by Ca$^{2+}$ and possible function in short-term synaptic plasticity. EMBO J. 29, 680–691
11. Kim, E. Y., Rumpf, C. H., Van Petegem, F., Arant, R. J., Findesen, F., Cooley, E. S., Isacoff, E. Y., and Minor, D. L., Jr. (2010) Multiple C-terminal tail Ca$^{2+}$/CaMs regulate Ca$^{2+}$ function but do not mediate channel dimersization. EMBO J. 29, 3924–3938
12. Köster, S., Pavkov-Keller, T., Köhlerbrandt, W., and Yildiz, Ö. (2011) Structure of human Na$^+$/H$^+$ exchanger NHE1 regulatory region in complex with calmodulin and Ca$^{2+}$. J. Biol. Chem. 286, 40954–40961
13. Izumi, Y., Watanabe, H., Watanabe, N., Aoyama, A., Jinbo, Y., and Hayashi, N. (2008) Solution x-ray scattering reveals a novel structure of calmodulin complexed with a binding domain peptide from the HIV-1 matrix protein p17. Biochemistry 47, 7158–7166
14. Schumacher, M. A., Rivard, A. F., Bächinger, H. P., and Adelman, J. P. (2001) Structure of the gating domain of a Ca$^{2+}$-activated K$^+$ channel complexed with Ca$^{2+}$/calmodulin. Nature 410, 1120–1124
15. Lu, Y., Jeffries, C. M., and Trewella, J. (2011) Invited review. Probing the structures of muscle regulatory proteins using small-angle solution scattering. Biopolymers 95, 505–516
16. Oakley, C. E., Hambly, B. D., Curmi, P. M., and Brown, L. J. (2004) Myosin-binding protein C. Structural abnormalities in familial hypertrophic cardiomyopathy. Cell Res. 14, 95–110
17. Oakley, C. E., Chamoun, J., Brown, L. J., and Hambly, B. D. (2007) Myosin-binding protein-C. Enigmatic regulator of cardiac contraction. Int. J. Biochem. Cell Biol. 39, 2161–2166
18. Flashman, E., Redwood, C., Moolman-Smook, J., and Watkins, H. (2004) Cardiac myosin-binding protein C. Its role in physiology and disease. Circ. Res. 94, 1279–1289
19. Gautel, M., Zuffardi, O., Freiburghaus, A., and Labeit, S. (1995) Phosphorylation switches specific for the cardiac isoform of myosin-binding protein C. A modulator of cardiac contraction? EMBO J. 14, 1952–1960
20. Tardiff, J. (2005) Sarcomeric proteins and familial hypertrophic cardiomyopathy. Linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail. Rev. 10, 237–248
21. Kelly, M., and Sensmarians, C. (2009) Multiple mutations in genetic cardiovascular disease. A marker of disease severity? Circ. Cardiovasc. Genet. 2, 182–190
22. van Dijk, S. J., Dooijes, D., dos Remedios, C., Michels, M., Lamers, J. M., Winegrad, S., Schlossarek, S., Carrier, L., ten Cate, F. J., Stienen, G. J., and van der Velden, J. (2009) Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119, 1473–1483
23. Gruen, M., Prinz, H., and Gautel, M. (1999) CAPK phosphorylation controls the interaction of the regulatory domain of cardiac myosin-binding protein C with myosin-S2 in an on-off fashion. FEBS Lett. 453, 254–259
24. Gruen, M., and Gautel, M. (1999) Mutations in β-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C. J. Mol. Biol. 286, 933–949
25. Kunst, G., Kress, K. R., Gruen, M., Uttenweiler, D., Gautel, M., and Fink, R. H. (2000) Myosin-binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ. Res. 86, 51–58
26. Mohamed, A. S., Dignam, J. D., and Schröder, K. K. (1998) Cardiac myosin-binding protein C (MyBP-C). Identification of protein kinase A and protein kinase C phosphorylation sites. Arch. Biochem. Biophys. 358, 313–319
27. Weisberg, A., and Winegrad, S. (1996) Alteration of myosin cross-bridges by phosphorylation of myosin-binding protein C in cardiac muscle. Proc. Natl. Acad. Sci. U.S.A. 93, 8999–9003
28. McClellan, G., Kulikovskaya, I., and Winegrad, S. (2001) Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys. J. 81, 1083–1092
29. Cheng, L. H., Qin, Q. H., Ding, G. L., Yao, H., Floyd, D., Woods, D., and Yang, Q. L. (2003) Substitution of a constantly phosphorylated cardiac myosin-binding protein C in transgenic mouse heart enhances cardiac performance. Circulation 108, (Suppl IV) 90
30. Yuan, C., Guo, Y., Ravi, R., Przyklenk, K., Shilkofski, N., Diez, R., Cole, R. N., and Murphy, A. M. (2006) Myosin-binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts. Evidence for novel phosphorylation sites. Proteomics 6, 4176–4186
31. Sadyayappan, S., Gulick, J., Osińska, H., Barefield, D., Cuello, F., Avkiran, M., Lasko, V. M., Lozenc, J. N., Mallet, M., Martin, J. L., Brown, J. H., Bers, D. M., Molkenstein, J. D., James, J., and Robbins, J. (2011) A critical function for Ser-282 in cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ. Res. 109, 141–150
32. Blumenthal, D. K., Charbonneau, H., Edelman, A. M., Hinds, T. R., Rosenberg, G. B., Storm, D. R., Vincenzi, F. F., Beavo, J. A., and Krebs, E. G. (1988) Synthetic peptides based on the calmodulin-binding domain of myosin light chain kinase inhibit activation of other calmodulin-dependent enzymes. Biochem. Biophys. Res. Commun. 156, 860–865
33. Tong, C. W., Gaffin, R. D., Zawieja, D. C., and Muthuchamy, M. (2004) Roles of phosphorylation of myosin-binding-protein C and troponin I in mouse cardiac muscle twitch dynamics. J. Physiol. 558, 927–941
34. Ding, P., Huang, J., Battiprolu, P. K., Hill, J. A., Kamk, K. E., and Stull, J. T. (2010) Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo. J. Biol. Chem. 285, 40819–40829

35. Sweeney, H. L., Bowman, B. F., and Stull, J. T. (1993) Myosin light-chain phosphorylation in vertebrate striated muscle. Regulation and function. Am. J. Physiol. 264, C1085-C1095

36. Zhi, G., Ryder, J. W., Huang, J., Chen, Y., Zhao, Y., Kamk, K. E., and Stull, J. T. (2005) Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. Proc. Natl. Acad. Sci. U.S.A. 102, 17519–17524

37. Solaro, R. J. (2008) Multiplex kinase signaling modifies cardiac function at the level of sarcomeric proteins. J. Biol. Chem. 283, 26829–26833

38. Ratti, J., Kesvatera, T., Jonsson, B., Akerfeldt, K. S., and Linse, S. (2004) Interactions of myosin-binding protein C domain C0. J. Biol. Chem. 286, 12650–12658

39. Lu, Y., Kwan, A. H., Trewhella, J., and Jeffries, C. M. (2011) The COC1 fragment of human cardiac myosin-binding protein C has common binding determinants for both actin and myosin. J. Mol. Biol. 413, 908–913

40. Jeffries, C. M., Lu, Y., Hynson, R. M., Taylor, J. E., Ballesteros, M., Kwan, A. H., and Trewhella, J. (2011) Human cardiac myosin-binding protein C. Structural flexibility within an extended modular architecture. J. Mol. Biol. 414, 735–748

41. Jeffries, C. M., Whittem, A. E., Harris, S. P., and Trewhella, J. (2008) Small-angle x-ray scattering reveals the N-terminal domain organization of cardiac myosin-binding protein C. J. Mol. Biol. 377, 1186–1199

42. Chow, J. Y., Jeffries, C. M., Kwan, A. H., Guss, J. M., and Trewhella, J. (2010) Calmodulin disrupts the structure of the HIV-1 MA protein. J. Mol. Biol. 400, 702–714

43. André, I., Kesvatera, T., Jonsson, B., Akerfeldt, K. S., and Linse, S. (2004) The role of electrostatic interactions in calmodulin-peptide complex formation. Biophys. J. 87, 1929–1938

44. Ababou, A., Rostkova, E., Mistry, S., Le Masurier, C., Gautel, M., and Pfuhl, M. (2008) Myosin-binding protein C positioned to play a key role in regulation of muscle contraction. Structure and interactions of domain C1. J. Mol. Biol. 384, 615–630

45. Franke, D., and Svergun, D. I. (2009) DAMMIF, a program for rapid ab initio shape determination in small-angle scattering. J. Appl. Crystallogr. 42, 342–346

46. Ababou, A., Gautel, M., and Pfuhl, M. (2007) Dissecting the N-terminal myosin binding site of human cardiac myosin-binding protein C. Structure and myosin binding of domain C2. J. Biol. Chem. 282, 9204–9215

47. Govada, L., Carpenter, L., da Fonseca, P. C., Hellwell, J. R., Rizkallah, P., Flashman, E., Chayen, N. E., Redwood, C., and Squire, J. M. (2008) Crystal structure of the C1 domain of cardiac myosin-binding protein-C. Implications for hypertrophic cardiomyopathy. J. Mol. Biol. 378, 387–397

48. Weljie, A. M., and Vogel, H. J. (2000) Tryptophan fluorescence of calmodulin binding domain peptides interacting with calmodulin containing unnatural methionine analogues. Protein Eng. 13, 59–66

49. Muñoz, P. L., and Callis, P. R. (2009) Solvent effects on the fluorescence quenching of tryptophan by amides via electron transfer. Experimental and computational studies. J. Phys. Chem. B 113, 2572–2577

50. Howarth, J. W., Ramisetti, S., Nolan, K., Sadayappan, S., and Rosevear, P. R. (2012) Structural insight into the unique cardiac myosin-binding protein-C motif. A partially folded domain. J. Biol. Chem. 287, 8254–8262

51. Yap, K. L., Kim, J., Truong, K., Sherman, M., Yuan, T., and Ikura, M. (2000) Calmodulin target database. J. Struct. Funct. Genomics 1, 8–14

52. Rhoads, A. R., and Friedberg, F. (1997) Sequence motifs for calmodulin recognition. FASEB J. 11, 331–340

53. Chattopadhyaya, R., Meador, W. E., Means, A. R., and Quiocio, F. A. (1992) Calmodulin structure refined at 1.7 Å resolution. J. Mol. Biol. 228, 1177–1192

54. Petoukhov, M. V., Konarev, P. V., Kikhney, A. G., and Svergun, D. I. (2007) ATSAS 2.1. Toward automated and web-supported small-angle scattering data analysis. J. Appl. Crystallogr. 40, S223–S228

55. Svergun, D. I. (1992) Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25, 495–503

56. Heidorn, D. B., and Trewhella, J. (1988) Comparison of the crystal and solution structures of calmodulin and troponin C. Biochemistry 27, 909–915

57. Matsushima, N., Hayashi, N., Jinbo, Y., and Izumi, Y. (2000) Ca2+-bound calmodulin forms a compact globular structure on binding four trifluoroperazine molecules in solution. Biochem. J. 347, 211–215

58. Jia, W., Shaffer, J. F., Harris, S. P., and Leary, J. A. (2010) Identification of novel protein kinase A phosphorylation sites in the m-domain of human and murine cardiac myosin-binding protein-C using mass spectrometry analysis. J. Proteome Res. 9, 1843–1853

59. Rybakova, I. N., Greaser, M. L., and Moss, R. L. (2011) Myosin-binding protein C interaction with actin. J. Biol. Chem. 286, 2008–2016

60. Harris, S. P., Lyons, R. G., and Bezold, K. L. (2011) In the thick of it. In vivo protein-C motif. A partially folded domain. J. Biol. Chem. 287, 9204–9215

61. Colbran, R. J. (2004) Targeting of calcium/calmodulin-dependent protein kinase II. Biochem. J. 378, 1–16

62. Stull, J. T., Kamk, K. E., and Vandenboom, R. (2011) Myosin light chain kinase and the role of myosin light chain phosphorylation in skeletal muscle. Arch. Biochem. Biophys. 510, 120–128

Human cMyBP-C Motif Interacts with Calmodulin